Table 2. Tractional retinal detachment characteristics following study injection in a randomised trial of ranibizumab prior to diabetic vitrectomy.
| Time point |
Control |
Ranibizumab |
||
|---|---|---|---|---|
| Baseline | 1 week | Baseline | 1 week | |
| TRD characteristics from ultrasound | ||||
| Number of eyes with TRD | 6 (40%) | 7 (47%) | 10 (67%) | 11 (73%) |
| Number of eyes with macula TRD involving | 5 (83%) | 5 (71%) | 5 (50%) | 5 (45%) |
| Dimensions of TRD (mean (SD)) | ||||
| Height (mm) | 2.2 (0.5) | 2.5 (0.6) | 2.4 (0.9) | 2.4 (1.0) |
| Base (mm) | 11.9 (5.0) × 13.2 (4.6) | 12.6 (5.3) × 13.5 (4.4) | 11.9 (4.7) × 11.5 (5.3) | 12.1 (5.0) × 12.5 (6.2) |
| Ultrasound-derived complexity score (0–8; median) | 4 | 4 | 5 | 5 |
| TRD characteristics from colour imaging (baseline only) | ||||
| Number with gradable images | 9 | — | 8 | — |
| Absent | 1 | 4 | ||
| Hammock | 3 | 3 | ||
| Diffuse central | 3 | 0 | ||
| Tabletop | 2 | 1 | ||
Abbreviation: TRD, tractional retinal detachment.